0Suppliers
11Customers
3Debt Items
20Related Chains

Zymeworks Inc. Suppliers

No suppliers on recordZymeworks Inc. has not yet been matched to upstream suppliers in our database, or is still being processed.

Zymeworks Inc. Customers

TickerNameConfidenceEvidence
DAIICHI-SANKYO DAIICHI-SANKYO 90% The decrease in total revenue was driven mainly by the achievement of non-recurring clinical milestone payments in 2025 of $14.0 million and $3.1 million from GSK and Daiichi Sankyo, respectively
BMY Bristol-Myers Squibb Company 85% Reciprocal relationship from BMY graph: Reciprocal relationship from ZYME graph: payments and royalties on potential future product sales we may receive. Importantly, these partnerships include predo…
BMY Bristol-Myers Squibb Company 85% payments and royalties on potential future product sales we may receive. Importantly, these partnerships include predominantly non-target-exclusive licenses for any of our therapeutic platforms, so w…
BMYMP Bristol-Myers Squibb Co 85% payments and royalties on potential future product sales we may receive. Importantly, these partnerships include predominantly non-target-exclusive licenses for any of our therapeutic platforms, so w…
BMYMP Bristol-Myers Squibb Co 85% Reciprocal relationship from BMYMP graph: Reciprocal relationship from ZYME graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from ZYME graph: Reciprocal relationship from BMYM…
CELGENE-ALPINE-INVESTMENT-CO-LLC CELGENE-ALPINE-INVESTMENT-CO-LLC 85% payments and royalties on potential future product sales we may receive. Importantly, these partnerships include predominantly non-target-exclusive licenses for any of our therapeutic platforms, so w…
JAZZ Jazz Pharmaceuticals plc 85% : $ , 2022: $ ) in research and development expense and general and administrative expense accounts. As of December 31, 2024, the total amount contributed by ESPP participants and not yet settled is …
JAZZ Jazz Pharmaceuticals plc 85% Reciprocal relationship from JAZZ graph: Reciprocal relationship from ZYME graph: : $ , 2022: $ ) in research and development expense and general and administrative expense accounts. As of December 3…
BEONE BEONE 80% These decreases were partially offset by higher royalty revenue from Jazz and BeOne in 2026
JNJ Johnson & Johnson 72% ne Medicines Ltd. (previously known as BeiGene, Ltd.) (“BeOne”): Milestone revenue Recognition of deferred revenue Drug supply Development support payments Royalties Johnson & Johnson Innovative Medi…
JNJ Johnson & Johnson 72% Reciprocal relationship from JNJ graph: Reciprocal relationship from ZYME graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from ZYME graph: Reciprocal relationship from JNJ grap…

Zymeworks Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
ZYME-DEBT Debt stack $17.0M 90% Market cache reports total debt of $17.0M.
ZYME-DEBT-13800 Xbrl Convertible 90% xbrl convertible detail from xbrl 2025-12-31.
ZYME-DEBT-13799 Warrants outstanding: 74 90% xbrl warrant detail from xbrl 2023-12-31.

Zymeworks Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Zymeworks Inc..

Zymeworks Inc. Ownership

HolderNameConfidenceEvidence
ZYME-OWNER-ECOR1-CAPITAL-LLC EcoR1 Capital, LLC 90% 13F overlay lists EcoR1 Capital, LLC as top holder; 221 tracked holders.

Zymeworks Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
BEAM Beam Therapeutics Inc. 100.00 2
BNRG Brenmiller Energy Ltd 100.00 2
CYTK Cytokinetics, Incorporated 100.00 2
ALXO ALX Oncology Holdings Inc. 100.00 2
CBIO Crescent Biopharma, Inc. 100.00 2
BNR Burning Rock Biotech Limited 100.00 2
BLLN BillionToOne, Inc. 100.00 2
BLRX BioLineRx Ltd. 100.00 2
ANIK Anika Therapeutics, Inc. 100.00 2
ANL Adlai Nortye Ltd. 100.00 2
WHWK Whitehawk Therapeutics, Inc. 100.00 2
ANRO Alto Neuroscience, Inc. 100.00 2
AXSM Axsome Therapeutics, Inc. 100.00 2
AORT Artivion, Inc. 100.00 2
AVBP ArriVent BioPharma, Inc. 100.00 2
CYTOF Altamira Therapeutics Ltd. 100.00 2
EMMA Emmaus Life Sciences, Inc. 100.00 2
CTMX CytomX Therapeutics, Inc. 100.00 2
BIOA BioAge Labs, Inc. 100.00 2
CCEP Coca-Cola Europacific Partners PLC 100.00 2